Cannabics Pharmaceuticals Stock Analysis
| CNBX Stock | USD 0.01 0 15.00% |
Cannabics Pharmaceuticals is overvalued with Real Value of 0.007119 and Hype Value of 0.01. The main objective of Cannabics Pharmaceuticals pink sheet analysis is to determine its intrinsic value, which is an estimate of what Cannabics Pharmaceuticals is worth, separate from its market price. There are two main types of Cannabics Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Cannabics Pharmaceuticals pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Cannabics |
Cannabics Pink Sheet Analysis Notes
About 58.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.8. Cannabics Pharmaceuticals had not issued any dividends in recent years. The entity had 1:120 split on the 12th of May 2022. CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. Cnbx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.The quote for Cannabics Pharmaceuticals is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Cannabics Pharmaceuticals please contact the company at 877 424 2429 or go to https://www.cnbxpharma.com.Cannabics Pharmaceuticals Investment Alerts
| Cannabics Pharmaceuticals had very high historical volatility over the last 90 days | |
| Cannabics Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Cannabics Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Cannabics Pharmaceuticals currently holds 1.6 M in liabilities with Debt to Equity (D/E) ratio of 0.48, which is about average as compared to similar companies. Cannabics Pharmaceuticals has a current ratio of 0.11, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cannabics Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Cannabics Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cannabics Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cannabics to invest in growth at high rates of return. When we think about Cannabics Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3.72 M) with profit before overhead, payroll, taxes, and interest of 7.16 K. | |
| Cannabics Pharmaceuticals currently holds about 96.28 K in cash with (1.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 58.0% of Cannabics Pharmaceuticals shares are held by company insiders |
Cannabics Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 123.28 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cannabics Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Cannabics Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 3rd of December, Cannabics Pharmaceuticals shows the Standard Deviation of 8.82, mean deviation of 2.19, and Risk Adjusted Performance of 0.0242. Cannabics Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cannabics Pharmaceuticals Price Movement Analysis
The output start index for this execution was twenty-seven with a total number of output elements of thirty-four. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cannabics Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cannabics Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Cannabics Pharmaceuticals Outstanding Bonds
Cannabics Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cannabics Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cannabics bonds can be classified according to their maturity, which is the date when Cannabics Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Cannabics Pharmaceuticals Predictive Daily Indicators
Cannabics Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cannabics Pharmaceuticals pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cannabics Pharmaceuticals Forecast Models
Cannabics Pharmaceuticals' time-series forecasting models are one of many Cannabics Pharmaceuticals' pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cannabics Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Cannabics Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Cannabics Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cannabics shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Cannabics Pharmaceuticals. By using and applying Cannabics Pink Sheet analysis, traders can create a robust methodology for identifying Cannabics entry and exit points for their positions.
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. Cnbx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Cannabics Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Cryptocurrency Center Now
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
| All Next | Launch Module |
Additional Tools for Cannabics Pink Sheet Analysis
When running Cannabics Pharmaceuticals' price analysis, check to measure Cannabics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannabics Pharmaceuticals is operating at the current time. Most of Cannabics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cannabics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannabics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cannabics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.